Advances in the Treatment of Acute ITP  

作　　者：Yuheng Jiang Jiahao Gu Zai Gu Yifeng Xu Bin Jia Jing Yang 

机构地区：[1]School of Emergency Trauma,Hainan Medical University,Haikou,Hainan,570100,China [2]School of Nursing,Hainan Medical University,Haikou,Hainan,570100,China

出　　处：《Journal of Integrative Medicine（双语）》2022年第1期22-28,共7页中西医结合杂志（英文）

摘　　要：Immune thrombocytopenia(ITP),also known as idiopathic thrombocyto­penic purpura,is a hematologic disease in which platelet destruction in­creases and production decreases,mainly mediated by immunity.However,up to now,the pathogenesis of ITP is not clear,which has caused great trouble in treatment.Therefore,this paper intends to review the recent lit­erature on ITP treatment to provide some reference for clinical treatment.This paper combines the evidence of ASH immune thrombocytopenia and the Chinese Guidelines for the Diagnosis and Treatment of Adult primary immune thrombocytopenia(2020 edition).In this paper,the treatment pro­cess of ITP was divided into first-line treatment and second-line treatment,and it was concluded that first-line treatment was often used when newly diagnosed with ITP:combination of high-dose dexamethasone and low-dose gamma globulin.However,it should be noted that only 60%-80%of patients responded to first-line treatment,and most of them relapsed during dosing reduction or drug withdrawal.Second-line treatment is recom­mended in this case.The standard treatment is splenectomy,but due to its uncontrollable nature and side effects,it should be used cautiously.A new treatment approach,thrombogenin receptor agonist,has great development potential,and multidrug combination therapy for ITP has positive clinical significance.

关 键 词：ITP Hormone therapy IVIg treatment SPLENECTOMY Thrombopoietin receptor agonist 

分 类 号：R55[医药卫生—血液循环系统疾病]